PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast - Benjamin M. Brucker, MD - Can We Improve Management of Overactive Bladder in Long-Term Care? Examining the Role of Beta-3 Adrenergic Agonists

Benjamin M. Brucker, MD - Can We Improve Management of Overactive Bladder in Long-Term Care? Examining the Role of Beta-3 Adrenergic Agonists

06/29/23 • 57 min

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

Go online to PeerView.com/QGG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Overactive bladder is frequently underdiagnosed and undertreated, but fortunately there's a newer treatment option with the beta-3 adrenoreceptor agonists. This class demonstrates efficacy without anticholinergic adverse effects, enabling you to provide optimal, patient-centered care for residents of long-term care facilities. This PeerView educational activity is designed to help improve your ability to accurately recognize overactive bladder, apply appropriate diagnostic criteria, and incorporate newer treatment options. Expert faculty explain the clinically relevant ways in which the newer beta-3 adrenoreceptor agonists differ from traditional antimuscarinics, as well as how they differ from each other with regard to selectivity and safety. Upon completion of this activity, participants should be better able to: Recognize the individual, clinical, and economic burdens of OAB specific to patients living in long-term care facilities; Engage members of the healthcare team to routinely screen long-term care residents for symptoms of OAB; Apply recommended diagnostic criteria to differentiate OAB from other urinary conditions with shared symptomatology; and Implement individualized OAB treatment plans that minimize risks related to cardiovascular health, cognitive impairment and dementia, and polypharmacy concerns.

Previous Episode

undefined - Kimberly Halla, MSN, FNP-C - Expert Nursing Insights on Personalized Care for Gynecologic Cancers: Educating and Supporting Patients on the Latest Therapeutic Approaches

Kimberly Halla, MSN, FNP-C - Expert Nursing Insights on Personalized Care for Gynecologic Cancers: Educating and Supporting Patients on the Latest Therapeutic Approaches

Go online to PeerView.com/VRD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the therapeutic landscape for gynecologic cancers (ovarian, endometrial, and cervical) rapidly evolves, how can oncology nurses effectively support patients and integrate the growing clinical evidence for approved and emerging strategies? Nurses can rise to the challenge with this PeerView Live MasterClass & Nursing Practice Forum, based on a recent live event developed in collaboration with the National Ovarian Cancer Coalition. An expert panel showcases what nursing professionals should know about diagnostic testing, PARP inhibitors, immunotherapy options, and managing potential adverse events. Through the lens of patient case scenarios, they will also share personal reflections on supporting patients throughout their treatment process. Upon completion of this activity, participants should be better able to: Review current efficacy and safety evidence of immunotherapy and PARP inhibitors in gynecologic malignancies such as endometrial, cervical, and ovarian cancers; Implement nurse-guided strategies to integrate approved and emerging systemic therapy options into personalized management and education plans for patients with gynecologic cancers, including information on diagnostic testing, therapeutic expectations, safety considerations, and clinical trial opportunities; and Apply effective team-based safety strategies to promptly identify, mitigate, manage, and counsel patients on the spectrum of adverse events associated with systemic therapy for endometrial, cervical, and ovarian cancers.

Next Episode

undefined - David M. O'Malley, MD - Endometrial Cancer Care in the Age of Immunotherapy: Translating Clinical Evidence Into Meaningful Improvements in Patient Outcomes Across the Disease Continuum

David M. O'Malley, MD - Endometrial Cancer Care in the Age of Immunotherapy: Translating Clinical Evidence Into Meaningful Improvements in Patient Outcomes Across the Disease Continuum

Go online to PeerView.com/UDV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While recurrent or advanced endometrial cancer (EC) has traditionally been associated with a poor prognosis, the use of immune checkpoint inhibition (ICI) in both monotherapy and combination approaches has led to improved outcomes. These gains have been well established in the second-line setting with multiple regulatory approvals, and ICIs have recently been shown to have an impact in the frontline setting, further altering the standard of care. In this activity, based on a recent live symposium, a panel of experts provides participants with foundational knowledge on the mechanistic rationale and up-to-date evidence supporting the use of ICIs in patients with advanced EC. Through discussion of real-life patient cases, the faculty provides practical guidance on incorporating approved and emerging approaches into clinical practice. Featured topics include biomarker testing, clinical trial enrollment, patient/provider education, and management of immune-related adverse events. Upon completion of this activity, participants should be better able to: Cite the rationales, therapeutic roles, and key efficacy/safety evidence supporting the use of immuno-oncology treatments and emerging approaches for patients with recurrent or advanced endometrial cancer; Select personalized treatment options for patients with recurrent or advanced endometrial cancer, taking into consideration the latest evidence, guideline recommendations, and biomarker testing results; and Implement proactive, collaborative strategies to mitigate and manage immune-related adverse events associated with immunotherapy-based treatment